Epaldeudomide Market Summary

Key Factors Driving Epaldeudomide Growth

1. Potential in hematological malignancies and inflammatory diseases

Kangpu Biopharmaceuticals lists epaldeudomide in development for multiple myeloma, non-Hodgkin lymphoma, immune thrombocytopenia, systemic lupus erythematosus, and inflammatory bowel disease. This broad development strategy could expand its future commercial opportunity if clinical studies establish efficacy across these conditions. The company's November 2025 announcement reported Phase I findings in heavily pretreated multiple myeloma patients, providing an additional basis for continued oncology development.

2. Progression into additional clinical trials

Kangpu's development pipeline includes a Phase IIb study for moderate-to-severe cutaneous manifestations of SLE, for which China's Center for Drug Evaluation approved the trial in April 2025. The company also received authorization from China's National Medical Products Administration in February 2025 to study KPG-818 in relapsed/refractory multiple myeloma. Advancement in these indications could expand the drug's future market opportunity, although trial initiation and approval do not guarantee commercial success.

3. Oral administration and potential treatment convenience

Epaldeudomide is an oral, once-daily small-molecule therapy. In the Phase IIa SLE study, 37 patients were randomized to receive 0.15 mg, 0.6 mg, or 2 mg once daily, or placebo, for 12 weeks. An oral formulation could offer a convenient alternative to injectable treatments for appropriate patients. Its long-term commercial value will depend on efficacy, tolerability, dosing requirements, and whether the safety profile supports sustained treatment.

4. Preliminary efficacy in multiple myeloma and other blood cancers

In its November 2025 announcement, Kangpu reported an overall response rate of 50% and a disease-control rate of 94% in heavily pretreated multiple myeloma patients in its Phase I study. The company also reported no febrile neutropenia or peripheral neuropathy in the study population. These early findings could support further evaluation in multiple myeloma and other hematological malignancies. However, the small early-stage study and reported treatment-related toxicities mean that larger studies are needed to establish the response rate, durability, and safety profile reliably.

Epaldeudomide Recent Developments

In November 2025, Kangpu Biopharmaceuticals announced that the company would deliver a poster presentation to highlight the Phase I clinical trial results of Epaldeudomide (KPG-818) for the treatment of hematological malignancies at the 67th American Society of Hematology (ASH) Annual Meeting.

“Epaldeudomide Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Epaldeudomide for potential indication like Inflammatory bowel diseases, Haematological malignancies, Multiple myeloma, Non-Hodgkin’s lymphoma, Behcet’s syndrome, Crohn’s disease, Idiopathic thrombocytopenic purpura, and Systemic lupus erythematosus in the 7MM. A detailed picture of Epaldeudomide’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Epaldeudomide for potential indications. The Epaldeudomide market report provides insights about Epaldeudomide’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Epaldeudomide performance, future market assessments inclusive of the Epaldeudomide market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Epaldeudomide sales forecasts, along with factors driving its market.

Epaldeudomide Drug Summary

Epaldeudomide, also known as KPG-818, is an investigational, orally administered small-molecule immunomodulatory drug developed by Kangpu Biopharmaceuticals for the treatment of autoimmune, inflammatory, and hematological disorders. It belongs to the class of cereblon (CRBN) E3 ubiquitin ligase modulators, often described as molecular glue degraders, which promote the degradation of specific proteins involved in immune regulation and cancer cell survival. Epaldeudomide binds to the CRBN-containing ubiquitin ligase complex and facilitates the degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors that regulate lymphocyte function and contribute to the survival and proliferation of certain malignant cells. Through this mechanism, the drug aims to modulate abnormal immune responses and exert antitumor activity. Its clinical development has explored potential applications in systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), chronic lymphocytic leukemia (CLL), adult T-cell leukemia/lymphoma (ATLL), and other immune-mediated or hematological conditions. Early-stage clinical studies have evaluated its safety, tolerability, pharmacokinetics, and preliminary therapeutic activity, including a Phase I/II study in patients with SLE. The oral formulation may offer a convenient treatment option compared with injectable therapies, although its clinical benefits and safety profile require further validation in larger studies. The report provides Epaldeudomide’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Epaldeudomide Market Report

The report provides insights into:

• A comprehensive product overview including the Epaldeudomide MoA, description, dosage and administration, research and development activities in potential indication like Inflammatory bowel diseases, Haematological malignancies, Multiple myeloma, Non-Hodgkin’s lymphoma, Behcet’s syndrome, Crohn’s disease, Idiopathic thrombocytopenic purpura, and Systemic lupus erythematosus.
• Elaborated details on Epaldeudomide regulatory milestones and other development activities have been provided in Epaldeudomide market report.
• The report also highlights Epaldeudomide‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Epaldeudomide market report also covers the patents information, generic entry and impact on cost cut.
• The Epaldeudomide market report contains current and forecasted Epaldeudomide sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Epaldeudomide market report also features the SWOT analysis with analyst views for Epaldeudomide in potential indications.

Methodology

The Epaldeudomide market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Epaldeudomide Analytical Perspective by DelveInsight

• In-depth Epaldeudomide Market Assessment

This Epaldeudomide sales market forecast report provides a detailed market assessment of Epaldeudomide for potential indication like Inflammatory bowel diseases, Haematological malignancies, Multiple myeloma, Non-Hodgkin’s lymphoma, Behcet’s syndrome, Crohn’s disease, Idiopathic thrombocytopenic purpura, and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Epaldeudomide sales data uptil 2034.

• Epaldeudomide Clinical Assessment

The Epaldeudomide market report provides the clinical trials information of Epaldeudomide for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Epaldeudomide Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Epaldeudomide Market Potential & Revenue Forecast

• Projected market size for the Epaldeudomide and its key indications
• Estimated Epaldeudomide sales potential (Epaldeudomide peak sales forecasts)
• Epaldeudomide Pricing strategies and reimbursement landscape

Epaldeudomide Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Epaldeudomide Market positioning compared to existing treatments
• Epaldeudomide Strengths & weaknesses relative to competitors

Epaldeudomide Regulatory & Commercial Milestones

• Epaldeudomide Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Epaldeudomide Clinical Differentiation

• Epaldeudomide Efficacy & safety advantages over existing drugs
• Epaldeudomide Unique selling points

Epaldeudomide Market Report Highlights

• In the coming years, the Epaldeudomide market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Epaldeudomide companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Epaldeudomide’s dominance.
• Other emerging products for Inflammatory bowel diseases, Haematological malignancies, Multiple myeloma, Non-Hodgkin’s lymphoma, Behcet’s syndrome, Crohn’s disease, Idiopathic thrombocytopenic purpura, and Systemic lupus erythematosus are expected to give tough market competition to Epaldeudomide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Epaldeudomide in potential indications.
• Analyse Epaldeudomide cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Epaldeudomide sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Epaldeudomide in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Epaldeudomide? How strong is Epaldeudomide’s clinical and commercial performance?
• What is Epaldeudomide’s clinical trial status in each individual indications such as Inflammatory bowel diseases, Haematological malignancies, Multiple myeloma, Non-Hodgkin’s lymphoma, Behcet’s syndrome, Crohn’s disease, Idiopathic thrombocytopenic purpura, and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Epaldeudomide Manufacturers?
• What are the key designations that have been granted to Epaldeudomide for potential indications? How are they going to impact Epaldeudomide’s penetration in various geographies?
• What is the current and forecasted Epaldeudomide market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Epaldeudomide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Epaldeudomide for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Epaldeudomide? What is the duration of therapy and what are the geographical variations in cost per patient?